Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
$20.55
-$0.35(-1.79%)
At close: 4:00 PM EST
$20.55
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.56M
Market Cap
$2.52B
Enterprise Value$2.12B
Total Cash (Recent Filing)$652.80M
Total Debt (Recent Filing)$2.99M
Price to Earnings (P/E)12.5
Beta0.85
Next Earnings
Nov 05, 2025EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding122,391,010
10 Day Avg. Volume1,234,511
30 Day Avg. Volume1,556,593
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.79
Enterprise Value/Gross Profit4.51
Enterprise Value/Ebitda7.71
Forecast
1Y Price Target
$33.00Price Target Upside60.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Agamree PerformanceThe strength of the Agamree launch continues to exceed early expectations with Agamree reporting strong revenue in its fifth full quarter since launch, building on momentum established earlier.
Commercial Business PerformanceCatalyst's commercial business remains robust with total product revenues exceeding consensus expectations.
Reimbursement MetricsReimbursement metrics remain high, with a significant percentage of shipments approved, indicating a positive environment for continued growth from Agamree.
Bears Say
Firdapse RevenueFirdapse revenue missed consensus due to underestimated impact from insurance claims disruption.
Firdapse Sales GuidanceFirdapse for LEMS posted 2Q sales of $85m, below the high-teens rate of growth in FY25 guidance.
Generic Competition RiskManagement flagged risk of additional generics as rationale for conservative FY25 guide.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.52B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Nov 05, 2025 which is in 15 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Aug 06, 2025. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.392 by $0.018.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.33.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,391,010 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.41 in its last earnings report, beating expectations of $0.392. Following the earnings report the stock price went down -9.867%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (60.58% Upside)
$33.00 (60.58% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 561.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $987.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.88%
12-Months-Change
Fundamentals
Return on Equity
28.49%
Trailing 12-Months
Asset Growth
37.59%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on developing innovative therapies for people with rare neurological diseases. The company primarily operates in the pharmaceutical sector and is known for its flagship product, Firdapse (amifampridine), which is approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and is being explored for other rare conditions. Catalyst Pharma aims to address unmet medical needs through its specialized drug development and commercialization efforts.
CPRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant revenue growth across key products, particularly FIRDAPSE and AGAMREE. However, challenges remain with the decline in FYCOMPA revenue due to generic competition and increased operational expenses. The strategic initiatives and strengthened leadership team position Catalyst for sustained growth, though uncertainties in patent litigation may impact future performance.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$33.00
▲(60.58% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
6.18% Insiders
17.46% Mutual Funds
0.51% Other Institutional Investors
50.81% Public Companies and Individual Investors